Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...